China's Innovative Drug Out-Licensing Value Crosses $120 Billion in 2026

Chinese pharmaceutical companies reached more than $120 billion in total out-licensing transactions so far in 2026, a 36 percent increase year on year, according to figures released by the National Medical Products Administration. Upfront payments exceeded $10 billion, reflecting higher deal sizes and growing overseas interest in domestic drug assets. Regulators also reported 59 innovative drugs and 51 innovative medical devices approved domestically year-to-date, alongside continued regulatory reforms aimed at accelerating clinical development and protecting clinical trial data.

The milestone underscores a transition in China's biopharma sector from cost-oriented generics to high-value original research that commands competitive terms in global markets. Crossing $10 billion in upfront receipts provides crucial cash flow for domestic biotechs facing tighter venture funding and domestic price pressures.

Cross-border out-licensing transactions by Chinese pharmaceutical developers have surpassed $120 billion so far this year, marking a 36 percent increase year on year, according to regulatory data published by Xinhua. The figures, disclosed by the National Medical Products Administration (NMPA) at the launch of the 2026 National Drug Safety Publicity Week, highlight sustained global demand for Chinese-developed therapeutic candidates. Within the headline transaction value, upfront payments exceeded $10 billion. The regulator noted that deal structures have seen average transaction values rise steadily, accompanied by a higher proportion of upfront cash and frequent major cross-border agreements. The licensing boom coincides with an expanding pipeline of domestic clinical trials and approvals. According to the NMPA, China logged more than 2,900 registered new drug clinical trials in 2025, an 18 percent increase year on year. Frontier segments showed particular momentum, with clinical trials for cell and gene therapies growing approximately 30 percent annually. Regulatory clearances inside China have kept pace with trial activity. Year-to-date, authorities have approved 59 innovative drugs and 51 innovative medical devices. Among these, 13 were first-in-class therapies featuring novel mechanisms of action or newly targeted biological pathways. Pediatric and rare disease treatments also saw accelerated market access. On the device front, the NMPA highlighted the domestic approval of what it termed the world's first implanted brain-computer interface system for hand motor function compensation. While outbound licensing accelerated, the agency also noted continued inbound commitments, with several multinational drugmakers expanding or constructing new research and manufacturing facilities across China. Looking ahead, NMPA officials said the regulator intends to deepen early-stage engagement with drug developers, adopting tailored guidance and synchronized research-and-review mechanisms for key therapeutic candidates. The agency also pledged to enforce clinical trial data protection rules, refine evaluation frameworks for Traditional Chinese Medicine, and maintain fast-track inspection channels for urgently needed clinical therapies.